Ventrus Biosciences FDA Presentation (Healthcare)

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Highlights

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Experienced Management Team

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Experienced Development Team

VEN 309: Iferanserin Novel Treatment for Hemorrhoids

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],VEN 309: Iferanserin Hemorrhoid Overview ,[object Object],[object Object],[object Object],[object Object]

VEN 309: Iferanserin Product Overview ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],VEN 309: Iferanserin Ready for Phase III

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],VEN 309: Iferanserin 1st Pivotal Phase III Study: Proposed Design

VEN 309: Iferanserin Phase III Endpoints Confirmed in Phase IIb (German Study) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

ANALYSIS* OF GERMAN PH IIB FOR PH III ENDPOINT Success with the Primary Endpoint for the Pivotal Trial German Study n = 111 * Post hoc VEN 309: Iferanserin Analysis of German Phase IIb for Phase III Endpoint* F g No Bleeding from day 7- day 14 (2 nd week of treatment) P = < .0001

VEN 309: Iferanserin German Phase IIb endpoints : Bleeding

VEN 309: Iferanserin German Phase IIb endpoints: Pain

VEN 309: Iferanserin German Phase IIb endpoints: Itching

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],VEN 309: Iferanserin Near Term Inflection Points

VEN 307: Diltiazem Cream Novel Treatment for Anal Fissures

[object Object],[object Object],[object Object],VEN 307: Diltiazem Cream Anal Fissures Overview ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],VEN 307: Diltiazem Cream Product Overview

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],VEN 307: Diltiazem Cream Phase III Initiated

[object Object],[object Object],[object Object],[object Object],VEN 307: Diltiazem Cream Near Term Timelines

Financial Summary ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Upcoming Milestones and News Flow VEN 307 VEN 309 SPA Granted Q1 2011 Q2 2011 Q3 2011 Q4 2011 Q1 2012 Q2 2012 Phase III Initiated German Phase IIB Trial Published Phase III Data Announced Ongoing Open Label Recurrence Data PTO Action on New IP Phase III Enrollment Completed New Formulations Selected with Long IP Complete Phase III Enrollment Phase III Data Announced PTO Action on Existing Patent Filing

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Multiple Future Scenarios Possible: Iferanaserin and Diltiazem

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],The Opportunity

Ventrus Biosciences FDA Presentation (Healthcare)

Recomendados

Recomendados

Más contenido relacionado

La actualidad más candente

La actualidad más candente (19)

Similar a Ventrus Biosciences FDA Presentation (Healthcare)

Similar a Ventrus Biosciences FDA Presentation (Healthcare) (20)

Más de Ventrus Biosciences

Más de Ventrus Biosciences (7)

Último

Último (20)

Ventrus Biosciences FDA Presentation (Healthcare)